{
"id":"mk19_a_on_s3",
"subspecialtyId":"on",
"title":"Ovarian Cancer",
"jsonContent":{
"type":"section",
"id":"mk19_a_on_s3",
"title":{
"__html":"Ovarian Cancer"
},
"titleNode":{
"type":"section-title",
"hlId":"2d1991",
"children":[
"Ovarian Cancer"
]
},
"children":[
{
"type":"section",
"id":"mk19_a_on_s3_1",
"title":{
"__html":"Epidemiology and Risk Factors"
},
"titleNode":{
"type":"section-title",
"hlId":"ba37ab",
"children":[
"Epidemiology and Risk Factors"
]
},
"children":[
{
"type":"p",
"hlId":"e2edc2",
"children":[
"Risk factors for epithelial ovarian cancer include mutations of ovarian cancer susceptibility genes, increasing age, infertility, nulliparity, endometriosis, polycystic ovary syndrome, and cigarette smoking."
]
},
{
"type":"p",
"hlId":"f1ef98",
"children":[
"The most common ovarian cancer susceptibility genes are ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"BRCA1"
]
},
", ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"BRCA2"
]
},
", and the mismatch repair (MMR) genes associated with Lynch syndrome. Approximately 10% to 15% of women with ovarian cancer carry a mutation in one of these genes, and all women with epithelial ovarian cancer should be offered germline genetic testing for ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"BRCA1"
]
},
" and ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"BRCA2"
]
},
" mutations. In patients with a personal or family history of other Lynch syndrome cancers (e.g., colorectal cancer, cancer of the endometrium or small bowel, transitional cell carcinoma of the ureter or renal pelvis), MMR mutation testing is recommended as well. The cumulative lifetime risk of ovarian cancer is 45% in ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"BRCA1"
]
},
" carriers and 3% to 12% in the other gene mutation carriers."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"5423af",
"children":[
"Genetic testing for ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"BRCA1"
]
},
" and ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"BRCA2"
]
},
" mutations should be offered to all women with ovarian cancer."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_a_on_s3_2",
"title":{
"__html":"Risk-Reduction Strategies and Screening"
},
"titleNode":{
"type":"section-title",
"hlId":"ee7589",
"children":[
"Risk-Reduction Strategies and Screening"
]
},
"children":[
{
"type":"p",
"hlId":"8cbb2c",
"children":[
"For women with ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"BRCA1, BRCA2,"
]
},
" or MMR gene mutations, prophylactic bilateral salpingo-oophorectomy is recommended after completion of childbearing. For ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"BRCA1"
]
},
" or ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"BRCA2"
]
},
" carriers, prophylactic bilateral salpingo-oophorectomy decreases the risk of ovarian cancers by greater than 80% and decreases all-cause mortality to age 70 years by 77%. Recommendations for genetic testing for breast and ovarian cancer syndromes are discussed in Breast Cancer."
]
},
{
"type":"p",
"hlId":"2dcbae",
"children":[
"Ovarian cancer screening with transvaginal ultrasonography or serum CA-125 is not recommended for patients of average risk and has no proven benefit even in women with high-risk genetic mutations."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"36b8a3",
"children":[
"For women with ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"BRCA1"
]
},
", ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"BRCA2"
]
},
", or MMR gene mutations, prophylactic bilateral salpingo-oophorectomy is recommended after completion of childbearing."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_a_on_s3_3",
"title":{
"__html":"Diagnosis"
},
"titleNode":{
"type":"section-title",
"hlId":"523223",
"children":[
"Diagnosis"
]
},
"children":[
{
"type":"p",
"hlId":"798bee",
"children":[
"Patients with ovarian cancer usually present at an advanced stage with bloating, abdominal or pelvic pain, constipation, or early satiety. Initial evaluation should include a pelvic examination, general physical examination, serum CA-125 level, complete blood count, liver chemistry tests, and transvaginal ultrasonography. Additional CT or MRI imaging are done as clinically indicated. Patients with a high suspicion of ovarian cancer should be referred to a gynecologic oncologist."
]
},
{
"type":"p",
"hlId":"45050a",
"children":[
"For early ovarian cancer, surgical exploration is recommended for diagnosis because removing the ovarian cancer intact without rupture improves survival. For advanced ovarian cancers with peritoneal masses, ascites, or pleural effusions, fluid cytology or image-guided biopsy can be done, particularly if the disease is not initially resectable and neoadjuvant chemotherapy may be used."
]
},
{
"type":"p",
"hlId":"5b50fc",
"children":[
"Staging and prognosis are shown in ",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_a_on_t07",
"wrapId":"1",
"children":[
"TableÂ 7"
]
}
]
},
". Early stage, low grade, serous histology, extent of disease after surgical debulking, and young age are associated with improved survival. A total of 31% of patients diagnosed with ovarian cancer survive 10 years, with one third of these long-term survivors having stage III or IV cancer."
]
},
{
"type":"inline-wrap",
"wrapId":"1",
"contentIds":[
"mk19_a_on_t07"
]
}
]
},
{
"type":"section",
"id":"mk19_a_on_s3_4",
"title":{
"__html":"Treatment"
},
"titleNode":{
"type":"section-title",
"hlId":"4c4ac0",
"children":[
"Treatment"
]
},
"children":[
{
"type":"p",
"hlId":"f807fc",
"children":[
"Surgical staging includes total hysterectomy, bilateral salpingo-oophorectomy, peritoneal washings, omentectomy, and pelvic and para-aortic lymph node sampling. Surgical debulking, including the resection of metastatic disease, improves prognosis. The volume of residual disease after surgery correlates inversely with survival. Neoadjuvant chemotherapy is recommended for patients with initially unresectable disease to shrink the tumor to facilitate surgical debulking."
]
},
{
"type":"p",
"hlId":"5f0d59",
"children":[
"Patients with early-stage ovarian cancer who have favorable histology may be treated with surgical resection alone. All other patients should receive adjuvant platinum-taxane chemotherapy. When incorporated into systemic therapy, intraperitoneal chemotherapy has been shown to improve survival in some trials, albeit with more toxicity, in women with stage III disease."
]
},
{
"type":"p",
"hlId":"88257d",
"children":[
"Women with advanced ovarian cancer and ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"BRCA1"
]
},
" or ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"BRCA2"
]
},
" mutations who achieve some response to traditional chemotherapy should receive subsequent maintenance therapy with olaparib, a poly (ADP-ribose) polymerase inhibitor."
]
},
{
"type":"p",
"hlId":"441a6b",
"children":[
"Second-look laparotomy to assess pathologic response is not beneficial."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"856297",
"children":[
"Patients with stage I ovarian cancer with favorable histology may be treated with surgery alone; all other patients should receive platinum-taxane chemotherapy."
]
},
{
"type":"keypoint",
"hlId":"d91422",
"hvc":true,
"children":[
"Second-look laparotomy to assess pathologic response following chemotherapy of ovarian cancer should not be performed."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_a_on_s3_5",
"title":{
"__html":"Monitoring and Follow-up"
},
"titleNode":{
"type":"section-title",
"hlId":"2c7993",
"children":[
"Monitoring and Follow-up"
]
},
"children":[
{
"type":"p",
"hlId":"acfbeb",
"children":[
"Posttreatment surveillance consists of physical and pelvic examinations every 3 to 6 months for 5 years, then annually. Surveillance of CA-125 levels may indicate early tumor progression but does not have an impact on survival. Other testing is recommended only to evaluate symptoms or findings suggesting recurrence."
]
}
]
},
{
"type":"section",
"id":"mk19_a_on_s3_6",
"title":{
"__html":"Management of Recurrent Ovarian Cancer"
},
"titleNode":{
"type":"section-title",
"hlId":"ffbd36",
"children":[
"Management of Recurrent Ovarian Cancer"
]
},
"children":[
{
"type":"p",
"hlId":"4365ef",
"children":[
"Despite optimal treatment, 80% to 85% of women with stage III or IV ovarian cancer will relapse. Patients who relapse 6 months or more after initial chemotherapy are considered to have platinum-sensitive disease, have a better prognosis, and are usually treated with platinum-containing combination chemotherapy. Adding the angiogenesis inhibitor bevacizumab to combination chemotherapy improves disease-free survival but increases the risk of serious gastrointestinal toxicities. For patients with platinum-resistant disease, various single agents can be used."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"168b87",
"children":[
"Patients who relapse more than 6 months after discontinuing platinum-based chemotherapy for ovarian cancer are considered to have platinum-sensitive disease and should be treated with platinum-based combination chemotherapy."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_a_on_s3_7",
"bibliography":true,
"title":{
"__html":"Bibliography"
},
"titleNode":{
"type":"section-title",
"hlId":"a7cc81",
"children":[
"Bibliography"
]
},
"children":[
{
"type":"references",
"children":[
{
"type":"reference",
"children":[
"Beral V, Gaitskell K, Hermon C, et al; Collaborative Group on Epidemiological Studies of Ovarian Cancer. Menopausal hormone use and ovarian cancer risk: individual participant meta-analysis of 52 epidemiological studies. Lancet. 2015;385:1835-42. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/25684585",
"target":"_blank"
},
"children":[
"PMID: 25684585"
]
},
" doi:10.1016/S0140-6736(14)61687-1"
]
},
{
"type":"reference",
"children":[
"Coleman RL, Brady MF, Herzog TJ, et al. Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2017;18:779-91. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/28438473",
"target":"_blank"
},
"children":[
"PMID: 28438473"
]
},
" doi:10.1016/S1470-2045(17)30279-6"
]
},
{
"type":"reference",
"children":[
"Cress RD, Chen YS, Morris CR, et al. Characteristics of long-term survivors of epithelial ovarian cancer. Obstet Gynecol. 2015;126:491-97. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/26244529",
"target":"_blank"
},
"children":[
"PMID: 26244529"
]
},
" doi:10.1097/AOG.0000000000000981"
]
},
{
"type":"reference",
"children":[
"Jacobs IJ, Menon U, Ryan A, et al. Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. Lancet. 2016;387:945-56. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/26707054",
"target":"_blank"
},
"children":[
"PMID: 26707054"
]
},
" doi:10.1016/S0140-6736(15)01224-6"
]
},
{
"type":"reference",
"children":[
"Kaufman B, Shapira-Frommer R, Schmutzler RK, et al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J Clin Oncol. 2015;33:244-50. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/25366685",
"target":"_blank"
},
"children":[
"PMID: 25366685"
]
},
" doi:10.1200/JCO.2014.56.2728"
]
},
{
"type":"reference",
"children":[
"Practice Bulletin No. 182 Summary: Hereditary Breast and Ovarian Cancer Syndrome. Obstet Gynecol. 2017;130:657-59. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/28832475",
"target":"_blank"
},
"children":[
"PMID: 28832475"
]
},
" doi:10.1097/AOG.0000000000002285"
]
},
{
"type":"reference",
"children":[
"Walker JL, Brady MF, Wenzel L, et al. Randomized trial of intravenous versus intraperitoneal chemotherapy plus bevacizumab in advanced ovarian carcinoma: an NRG Oncology/Gynecologic oncology group study. J Clin Oncol. 2019;37:1380-90. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/31002578",
"target":"_blank"
},
"children":[
"PMID: 31002578"
]
},
" doi:10.1200/JCO.18.01568"
]
},
{
"type":"reference",
"children":[
"Wright AA, Bohlke K, Armstrong DK, et al. Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: society of gynecologic oncology and american society of clinical oncology clinical practice guideline. J Clin Oncol. 2016;34:3460-73. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/27502591",
"target":"_blank"
},
"children":[
"PMID: 27502591"
]
},
" doi:10.1200/JCO.2016.68.6907"
]
}
]
}
]
}
]
},
"tablesContent":{
"mk19_a_on_t07":{
"id":"mk19_a_on_t07",
"number":7,
"bookId":"on",
"title":{
"__html":"International Federation of Gynecology and Obstetrics Ovarian Cancer Staging, Treatment, and Survival"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"205dfa",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 7. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_a_on_t07"
}
]
},
"International Federation of Gynecology and Obstetrics Ovarian Cancer Staging, Treatment, and Survival"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"64c6da",
"class":"col hd l",
"children":[
"Stage"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"0b890b",
"class":"col hd l",
"children":[
"Definition"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"4c4ac0",
"class":"col hd l",
"children":[
"Treatment"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"629953",
"class":"col hd l",
"children":[
"5-Year Survival"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"63bf80",
"class":"cell txt l",
"children":[
"Stage I disease (favorable)",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
}
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"673f4b",
"class":"cell txt l",
"children":[
"Cancer in one or both ovaries, not high grade or clear cell, negative peritoneal washings, no rupture"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"49130e",
"class":"cell txt l",
"children":[
"Surgery alone"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"525e05",
"class":"cell txt l",
"children":[
"94% overall survival"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b928a8",
"class":"cell txt l",
"children":[
"Stage I disease (unfavorable); stage II disease"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d77a3a",
"class":"cell txt l",
"children":[
"Unfavorable stage I disease: confined to ovaries but with high-grade or clear cell histology, rupture, or positive peritoneal washings"
]
},
" ",
{
"type":"p",
"hlId":"b64c65",
"class":"cell txt l",
"children":[
"Stage II disease: spread beyond ovaries but confined to pelvis"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"9fe44a",
"class":"cell txt l",
"children":[
"Surgery followed by 3 to 6 cycles of chemotherapy (usually carboplatin and paclitaxel)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"0e7b44",
"class":"cell txt l",
"children":[
"Stage I: 85% relative survival",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"b"
]
}
]
},
" ",
{
"type":"p",
"hlId":"8254ce",
"class":"cell txt l",
"children":[
"Stage II: 70%-78% relative survival"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"3b82ba",
"class":"cell txt l",
"children":[
"Optimally debulked stage III disease"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ba6d4d",
"class":"cell txt l",
"children":[
"Spread to abdomen, with residual tumor masses <1 cm after debulking surgery"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"1627f8",
"class":"cell txt l",
"children":[
"Surgery followed by IV or IV/IP chemotherapy"
]
},
" ",
{
"type":"p",
"hlId":"77ea36",
"class":"cell txt l",
"children":[
"Maintenance olaparib after first-line chemotherapy"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"251a80",
"class":"cell txt l",
"children":[
"IV chemotherapy: 40% overall survival"
]
},
" ",
{
"type":"p",
"hlId":"e736ca",
"class":"cell txt l",
"children":[
"IV/IP chemotherapy: 50% overall survival (23% decreased risk of death with IP/IV versus IV chemotherapy)"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"fb2226",
"class":"cell txt l",
"children":[
"Suboptimally debulked stage III disease or stage IV disease",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"c"
]
}
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"cbdb6a",
"class":"cell txt l",
"children":[
"Stage III (suboptimal) disease: spread to abdomen with residual masses >1 cm after debulking surgery"
]
},
" ",
{
"type":"p",
"hlId":"e8265b",
"class":"cell txt l",
"children":[
"Stage IV disease: spread beyond abdomen"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"4af228",
"class":"cell txt l",
"children":[
"Surgery (usually done even for stage IV disease as it improves survival) and chemotherapy; preoperative (neoadjuvant) chemotherapy given for initially unresectable cancer"
]
},
" ",
{
"type":"p",
"hlId":"77ea36",
"class":"cell txt l",
"children":[
"Maintenance olaparib after first-line chemotherapy"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"bb3295",
"class":"cell txt l",
"children":[
"Stage III: 39% relative survival"
]
},
" ",
{
"type":"p",
"hlId":"2f0731",
"class":"cell txt l",
"children":[
"Stage IV: 17% relative survival"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
"IP = intraperitoneal; IV = intravenous."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
},
"Careful staging is critical: almost one third of patients with apparent early disease will have more advanced disease when thorough staging is completed."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"b"
]
},
"Relative survival is the ratio of the proportion of observed survivors in a cohort of patients with cancer to the proportion of expected survivors in a comparable set of cancer-free individuals."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"c"
]
},
"According to recent guidelines by the American Society of Clinical Oncology and the Society of Gynecologic Oncology, patients with stage IIIC or IV ovarian cancer who are at high perioperative risk or who have a low likelihood of optimal tumor debulking should receive neoadjuvant chemotherapy followed by reevaluation for cytoreductive surgery."
]
]
}
}
}